About IBB ETF
Biotechnology is the 'next big thing' in the technology sector. The Blackrock Biotechnology ETF (IBB) provides targeted exposure to equities in the biotechnology and pharmaceuticals sectors trading on the NASDAQ.
Returns
| Performance | YTD | 1Y | 3Y | 5Y | 10Y |
|---|---|---|---|---|---|
| Blackrock Biotechnology ETF | 7.95% | 35.79% | 13.68% | 12.22% | 18.18% |
Asset Class
Asset type breakdown
IBB Holdings - Top 10
| Namei | Weightage (%) | |
|---|---|---|
| Amgen Inc | 8.14% | |
| Gilead Sciences, Inc | 6.58% | |
| Vertex Pharmaceuticals Incorporated | 4.87% | |
| Illumina, Inc | 4.51% | |
| Regeneron Pharmaceuticals, Inc | 4.40% | |
| Moderna, Inc | 4.13% | |
| Biogen Inc | 3.26% | |
| Alexion Pharmaceuticals, Inc | 2.71% | |
| Seagen Inc | 2.63% | |
| AstraZeneca PLC | 2.02% |
IBB Sectors/Industry Breakdown
| Sectori | % of market value | |
|---|---|---|
| Healthcare | 100% |
IBB Countries
| Country | % of market value | |
|---|---|---|
| North America | 90.18% | |
| Europe Developed | 3.79% | |
| Asia Emerging | 3.22% | |
| United Kingdom | 2.48% | |
| Asia Developed | 0.17% | |
| Africa/Middle East | 0.17% |
Projected Returns
Returnsbased on historic SIP returns of 16.01% per annum
IBB Summary Data
| Fund Size(AUM) | $ | i |
| Avg. mkt. cap (MM) | $ | i |
| Symbol | IBB | |
| Exchange | XNAS | |
| ISIN | US4642875565 |
| Cat. Benchmark | MSCI ACWI NR USD | |
| Asset class | EQUITY | |
| Category | Health | |
| Country | US |
IBB Portfolio Data & Volatility Analysis
| Expense ratio | 0.46 | i |
| Beta | 0.94 | i |
| P/E ratio | 12.99893 | i |
| Standard Deviation | 23.09 | i |
Fund Strategy
iShares Nasdaq Biotechnology ETF is an exchange-traded fund incorporated in the USA. The Fund's objective seeks investment results that correspond to the performance of the Nasdaq Biotechnology Index. The Fund will concentrate its investments in companies primarily engaged in using biomedical research for the discovery or development of new treatments or cures for human disease.
IBB Fact Sheets & Reports
About iShares by Blackrock
With more than twenty years of ETF experience, a global line-up of 800+ exchange-traded funds (ETFs) and $1.9 trillion in assets under management, iShares continually strives to unlock new opportunities for our investors. By channeling strategic thinking and expertise into a robust offering of investment funds, iShares aims to make wealth-building easier, more efficient, and more rewarding for all investors.
